Category:

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to […]

September 3, 2024

Deriv célèbre son 25e anniversaire avec la récompense “UK’s Best Workplaces in Financial Services & Insurance™”

L’équipe de Deriv basée au Royaume-Uni célèbre la récompense Best Place to Work Deriv a également renouvelé les certifications Great Place to Work de ses bureaux basés au Royaume-Uni et dans six autres pays Célèbre 25 années passées à créer une culture d’entreprise positive L’équipe de Deriv basée au Royaume-Uni célèbre la récompense Best Place […]

September 3, 2024

José Sayovo’s record represents pride for Angola

The consideration comes from the secretary general of the Angola Paralympic Committee (CPA), António da Luz, reacting to ANGOP, in Paris, after Venezuelan A. Santos won gold with a time of 50.58 in the same distance for visually impaired athletes, Su…

September 3, 2024

EMAIL NEWSLETTER

Subscribe to receive inspiration, ideas, and news in your inbox

  • Trending

1.

2.

3.

4.

5.

  • Recent
  • Advertisement